Acadia
Acadia Pulls Plug on Prader-Willi Drug After Phase 3 Trial Failure
Acadia Pharmaceuticals; Prader-Willi syndrome; carbetocin; ACP-101; phase 3 trial; hyperphagia; clinical trial failure; Soleno Therapeutics; Vykat XR
Acadia Halts Development of Nasal Prader-Willi Drug After Phase 3 Failure
Acadia Pharmaceuticals; carbetocin; Prader-Willi syndrome; Phase 3 trial; COMPASS PWS study; clinical trial failure; nasal spray; hyperphagia
Acadia Pharmaceuticals Secures Exclusive Licensing Deal for Saniona’s Tremor Treatment Asset Worth Up to $582 Million
Acadia Pharmaceuticals, Saniona, tremor treatment, licensing deal, biobucks, neurological disorder
Acadia Pharmaceuticals Secures Exclusive License for SAN711, a Novel Essential Tremor Treatment
Acadia Pharmaceuticals, SAN711, Essential Tremor, Licensing Agreement, Saniona, GABAA-α3 Positive Allosteric Modulator
Acadia Generates $100 Million from Pediatric Disease Priority Review Voucher Sale
Acadia Pharmaceuticals, Pediatric Disease Priority Review Voucher, Pharmaceutical Industry, Financial Transactions